Search
Powered By HealthLine
Special Offers
Health Tools
 Depression Basics
 Antidepressant Drug Info
 Depression Q&A
 Depression Support Groups
 Depression Related Disorders
Featured Conditions
 Depression
 Anxiety
 Sleep
 Bipolar
Resources
Healthscout News
3D Health Animations
Health Videos
Quizzes & Tools
Health Encyclopedia
Library & Communities
News Archive
Drug Library
Find a Therapist
Enter City or Zip Code:
Powered by Psychology Today



Channels
Home |  Today | Women| Men| Kids| Seniors| Diseases| Addictions| Sex & Relationships| Diet, Fitness, Looks| Alternative Medicine| Drug Checker
 Printer Friendly  Send to a Friend

Antipsychotic Drug Boosts Risk of Heart Disease, Diabetes

French study in rats finds olanzapine changes metabolism in weeks


Related Encyclopedia
 border=
Abdominoplasty
Acidophilus
Addison's Disease
Alzheimer's Disease
More...

Related Healthscout Videos
 border=
Nutrition and Cancer
Nutrition and Osteoporosis
Importance of Good Nutrition
Controlling Incontinence
More...

Related Animations
 border=
Alzheimer's Disease Video Animation
Angioplasty
Bipolar Disorder Animation
Coronary Bypass Surgery
More...

Related Drug Information
 border=
Accupril
Actonel
Actos
Adderal XR
More...

Related News Articles
 border=
Little-Known Fat Can Be a Heartbreaker
Is Human Growth Hormone a Key to Longevity?
Antibiotics May Not Cause Diarrheal Bacteria
Racial Disparities Exist in Head and Neck Cancer Outcomes
More...

MONDAY, April 7 (HealthDay News) -- Use of the antipsychotic medication olanzapine may put a person at an increased risk for heart disease and type 2 diabetes, new findings show.

A team of French researchers studying the drug's effect on male rats found that, after consuming olanzapine over several weeks, the rodents' blood sugar levels rose significantly compared to rats not on the drug. This was especially noticeable after the rats ate meals with glucose in them. The rats consuming olanzapine did not gain weight or increase their food intake; however, the proportion of fat stored in their abdominal cavity was notably higher.

Text Continues Below



These changes are increased risk factors of metabolic syndrome, which puts an individual at greater risk of heart disease and type 2 diabetes.

"Based on these findings, we concluded that male rats treated with olanzapine experienced an early disruption of energy metabolism. This was a result of the fat tissue we observed and the impairment in blood sugar regulation which are both associated with metabolic syndrome and subsequent risk of diabetes," senior study author Dominique Hermier, of the Department of Human Nutrition, INRA, in Paris, said in a prepared statement.

The study was to be presented Monday at the Experimental Biology annual meeting, in San Diego.

Olanzapine is a part of the second generation of antipsychotics known as atypical antipsychotics being used to treat schizophrenia. These newer medicines have proven as effective as their predecessors in treating the delusions and hallucinations that accompany psychotic mental illness and even more effective in combating other symptoms, such as apathy. Side effects, though, include weight gain and a greater chance for developing metabolic syndrome. Physicians fear these side effects may cause their patients to stop taking their medicine.

"Atypical medications like olanzapine are of tremendous value in treating individuals with certain kinds of mental illness. Our hope is that through discoveries such as this one, such life-enhancing medicines can be further optimized," Hermier said.

More information

The American Heart Association has more about metabolic syndrome.



-- Kevin McKeever

Copyright © 2008 ScoutNews, LLC. All rights reserved.
Last updated 4/7/2008

Related Links
 border=
From Healthscout's partner site on depression, MyDepressionConnection.com
UNDERSTAND: Get a full understanding of depression
TREATMENT: Learn how therapy and lifestyle changes can help
DRUGS: Common drugs used to treat depression





SOURCE: American Physiological Society, news release, April 7, 2008


We comply with the HONcode standard for trustworthy health
information:
verify here.
About The HealthScout Network Contact Us
Copyright © 2001-2008. The HealthCentralNetwork, Inc. All rights reserved.
Privacy Policy  Terms of Service